Back to News Page
Emily Mirro, Co-Founder & President of SynchNeuro, discusses how brain-based technology is enabling a proactive, personalized approach to cardiometabolic health and early intervention.
Source: Tech Point
Boomerang Ventures is backing SynchNeuro’s pioneering effort to build the world’s first brain-based, non-invasive continuous glucose monitor. Using EEG-derived brainwave signals decoded by machine learning, SynchNeuro aims to track blood glucose and cardiometabolic indicators via a discreet wearable placed behind the ear. This seed-stage investment will help speed development of the “Cardiometabolic Advisor” system and bring proactive, needle-free monitoring closer to mass market.
Source: Business Insider
Boomerang Ventures has announced a seed-stage investment in SynchNeuro, a Philadelphia-based startup developing a brain-based, non-invasive wearable sensor to monitor blood glucose and other vital health metrics in real time. The firm’s backing supports SynchNeuro’s mission to use EEG-derived data and machine learning for proactive, needle-free cardiometabolic health insights.
Boomerang Ventures has announced a seed-stage investment in SynchNeuro, a pioneering neurotechnology company developing the world’s first brain-based, non-invasive continuous glucose monitor. The partnership accelerates SynchNeuro’s mission to revolutionize cardiometabolic health through EEG-based technology that interprets brain signals to track blood glucose and other vital metrics in real time. This innovative approach aims to make proactive, pain-free, and affordable glucose monitoring accessible to millions.
Back to News Page
